Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Other Operating Expenses (2022 - 2025)

Spero Therapeutics' Other Operating Expenses history spans 3 years, with the latest figure at $587000.0 for Q3 2025.

  • For Q3 2025, Other Operating Expenses changed N/A year-over-year to $587000.0; the TTM value through Dec 2025 reached $587000.0, changed N/A, while the annual FY2025 figure was $587000.0, N/A changed from the prior year.
  • Other Operating Expenses reached $587000.0 in Q3 2025 per SPRO's latest filing, down from $5.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $11.8 million in Q2 2022 to a low of $587000.0 in Q3 2025.
  • Average Other Operating Expenses over 3 years is $6.6 million, with a median of $6.9 million recorded in 2022.